Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 7/20 | 0.41 |
| ▸ | APOB | P04114 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11898829 | 1.00 | CA1 (0.47) | CA1CA2ACHETACR1CCR2 | |
| SCHEMBL7896643 | 0.87 | TACR1 (0.47) | CA1CA2ACHETACR1MTTP | |
| SCHEMBL11898600 | 0.84 | TACR1 (0.44) | CA1CA2ACHETACR1CCR2 | |
| SCHEMBL1421067 | 0.81 | CA1 (0.59) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL1590778 | 0.81 | CA1 (0.59) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL1421070 | 0.81 | CA1 (0.59) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL11898633 | 0.80 | NOTUM (0.44) | CA1CA2ALDH1A1GAATSHR | |
| SCHEMBL7898428 | 0.80 | NOTUM (0.44) | CA1CA2ALDH1A1GAATSHR | |
| SCHEMBL11899768 | 0.79 | GRIA2 (0.47) | CCR2MTTPAPOB | |
| SCHEMBL7898932 | 0.79 | GRIA2 (0.47) | CCR2MTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | CA1 924/4885CA2 1577/4885ACHE 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.